Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cinnamic Acid Conjugated With Triazole Acetamides As Anti-Alzheimer and Anti-Melanogenesis Candidates: An in Vitro and in Silico Study Publisher Pubmed



Shokouhi Asl AS1 ; Sayahi MH2 ; Hashempur MH3 ; Irajie C4 ; Alaeddini AH5 ; Ghafouri SN5 ; Noori M8 ; Dastyafteh N8 ; Mottaghipisheh J6 ; Asadi M1 ; Larijani B1 ; Mahdavi M8 ; Iraji A7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medicinal Chemistry, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Chemistry, Payame Noor University, Tehran, Iran
  3. 3. Research Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. School of Chemistry, College of Science, University of Tehran, Tehran, Iran
  6. 6. Department of Aquatic Sciences and Assessment, Swedish University of Agricultural Sciences, SE-750 07, Uppsala, 7050, Sweden
  7. 7. Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  8. 8. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Scientific Reports Published:2025


Abstract

In this study, new cinnamic acid linked to triazole acetamide derivatives was synthesized and evaluated for anti-Alzheimer and anti-melanogenesis activities. The structural elucidation of all analogs was performed using different analytical techniques, including 1H-NMR, 13C-NMR, mass spectrometry, and IR spectroscopy. The synthesized compounds were assessed in vitro for their inhibitory activities against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and tyrosinase enzymes. Among synthesize derivative compound 3-(4-((1-(2-((2,4-dichlorophenyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)acrylic acid (10j) exhibited the highest activity against BChE with an IC50 value of 11.99 ± 0.53 µM. Derivative 3-(3-methoxy-4-((1-(2-oxo-2-(p-tolylamino)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)acrylic acid (10d), bearing a 4-CH3 group, was identified as the most potent AChE inhibitor. In terms of tyrosinase inhibition, 3-(3-methoxy-4-((1-(2-((2-methyl-4-nitrophenyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)acrylic acid (compound 10n), demonstrated 44.87% inhibition at a concentration of 40 µM. Additionally, a kinetic study of compound 10j which 2,4-dichlorophenyl substituents against BChE revealed a mixed-type inhibition pattern. Furthermore, molecular docking and molecular dynamic studies of compound 10j were conducted to thoroughly evaluate its mode of action within the BChE active site. © The Author(s) 2025.